07.12.2018 Carl Zeiss Meditec AG  DE0005313704

DGAP-News: Carl Zeiss Meditec continues on growth course in fiscal year 2017/18


 

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec continues on growth course in fiscal year 2017/18

07.12.2018 / 07:00
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec continues on growth course in fiscal year 2017/18
 
Both strategic business units make good contributions / Significant increases in Americas and APAC regions
 

JENA, 7 December 2018

Carl Zeiss Meditec AG increased its revenue further in all strategic business units and regions after twelve months of fiscal year 2017/18. Revenue increased by 7.6 percent (adjusted for currency effects: 11.1 percent), to EUR1,280.9m (prior year: EUR1,189.9m). Earnings before interest and taxes (EBIT) rose to EUR197.1m (prior year: EUR180.8m). The EBIT margin remained stable at 15.4 percent (prior year: 15.2 percent). Earnings per share reached EUR1.41 (prior year: EUR1.57).
 

"We achieved our sales forecast, which we had already raised in July 2018 - in spite of negative currency effects. In fiscal year 2017/18 we gained further market shares in both ophthalmology and microsurgery. What is particularly encouraging is that all regions and business segments contributed - the performance of the Americas and Asia/Pacific regions was particularly strong," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
 

Solid growth and market share gains in both strategic business units

The strategic business unit (SBU) Ophthalmic Devices increased its revenue by 6.0 percent after twelve months of fiscal year 2017/18 (adjusted for currency effects: 9.3 percent), to EUR933.3m, compared with EUR880.5m in the same period of the prior year. The laser systems business for vision correction and the diagnostics business developed particularly well. There was also continued solid demand for premium and standard intraocular lenses for the treatment of cataracts.

Revenue in the Microsurgery SBU grew by 12.3 percent (adjusted for currency effects: 16.5 percent), to EUR347.6m, compared with EUR309.4 in the prior year. This growth is particularly attributable to the new products for the neurosurgery and dental segments.

 

Significant growth, particularly in Americas and APAC regions

Revenue in the EMEA region increased by 4.0 percent (adjusted for currency effects: 5.4 percent), to EUR378.1m (prior year: EUR363.4m). Development in the core markets Germany and France was stable. Increases were achieved in the UK, Southern Europe and some Eastern European markets.

A positive trend was also recorded in the Americas region. Revenue increased to EUR406.5m (prior year: EUR378.2m). This growth amounted to 7.5 percent (adjusted for currency effects: 14.4 percent) and thus accelerated significantly compared with the prior year. This is primarily due to a continued positive trend in the U.S. market.

The Asia/Pacific (APAC) region grew by 10.7 percent, to EUR496.3m (prior year: EUR448.2m). After adjustment for currency effects, this corresponds to an increase of 13.2 percent. Once again, the largest contributions to growth came from China and South Korea.

The EBIT margin was 15.4 percent (prior year: 15.2 percent). Adjusted for special effects, an increase to 15.7 percent was recorded (prior year: 14.8 percent). This was due in particular to a positive development of the product mix. Revenue from recurring business, such as from consumables, implants and services, increased further, and climbed to around 34 percent of revenue (prior year: 33 percent).

Earnings per share declined slightly, to EUR1.41 (prior year: EUR1.57). This decrease was attributable to negative currency effects and to the increased number of shares.

Carl Zeiss Meditec AG anticipates further growth for fiscal year 2018/19, at least to the level of the underlying markets. The EBIT margin is expected to range between 14 percent and 16 percent in fiscal year 2018/19 and in the medium term.
 

Revenue by strategic business unit

All figures in EURm 12 months 2017/18 12 months 2016/17 Change from prior year Change from prior year (adjusted for currency effects)
Ophthalmic Devices 933.3 880.5 +6.0% +9.3%
Microsurgery 347.6 309.4 +12.3% +16.5%
Total 1,280.9 1,189.9 +7.6% +11.1%
 

 

Revenue by region

All figures in EURm 12 Months 2017/18 12 Months 2016/17 Change from prior year Change from prior year (adjusted for currency effects)
EMEA 378.1 363.4 +4.0% +5.4%
Americas 406.5 378.2 +7.5% +14.4%
APAC 496.3 448.2 +10.7% +13.2%
Total 1,280.9 1,189.9 +7.6% +11.1%
 

 

Contact for investors and press
Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: [email protected]

www.zeiss.com

 



07.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

755399  07.12.2018 

fncls.ssp?fn=show_t_gif&application_id=755399&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 1.088,37 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.710,00
EBITDA1,2 174,56 205,07 228,41 313,03 237,98 435,20 407,50
EBITDA-Marge3 16,04 17,23 17,83 21,45 17,82 26,43 23,83
EBIT1,4 154,33 180,83 197,13 264,66 177,55 373,61 344,00
EBIT-Marge5 14,18 15,20 15,39 18,14 13,30 22,69 20,12
Jahresüberschuss1 99,97 135,78 126,23 160,58 123,42 237,52 221,00
Netto-Marge6 9,19 11,41 9,86 11,00 9,24 14,42 12,92
Cashflow1,7 111,77 37,73 187,21 219,63 178,53 362,66 0,00
Ergebnis je Aktie8 1,21 1,57 1,41 1,79 1,37 2,64 2,42
Dividende8 0,42 0,55 0,55 0,65 0,50 0,90 0,90
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

XETR:AFX Charts by TradingView (c)


INVESTOR-INFORMATIONEN
©boersengefluester.de
Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 147,400 Halten 13.183,54
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
46,79 31,92 1,47 96,66
KBV KCV KUV EV/EBITDA
8,35 36,35 8,01 28,13
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,50 0,90 0,61 30.03.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.02.2022 13.05.2022 05.08.2022 10.12.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-16,14% -13,09% -20,26% 25,02%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei DGAP abrufen


Medtech , 531370 , AFX , XETR:AFX